Operator fluency on fresh ground: management answers probing questions about a new driver with unhesitating operational
The model's full reasoning — Q2 2023 call → NOWe need to determine if the transcript shows the dynamic described: a recently emerged positive element, probed by analysts, and management responds with unhesitating, granular operational command across at least two exchanges, conveying that the element's contribution is still early. The recently emerged positive element: The Janssen partnership. It was signed recently (first half 2023). Analysts probe it. Specifically, Lucy Codrington asks about "payment in kind support for 312" and "IO combination, Phase 3 and beyond" regarding J&J's commitment. Also another analyst asks about Hensify in soft tissue sarcoma and LianBio. But the question is about a "recently emerged positive element" that is "real and current" and "young" - new to meaningful contribution within recent quarters. The Janssen deal is indeed recent. Management responds to questions about it. However, does management provide granular operational detail? Let's examine. Lucy asks: "in terms of the payment in kind support for 312, when can we expect that to begin from J&J?" Laurent responds: "we've been initiating this contract in July, became effective in August and since then we've been working a lot with the Johnson & Johnson team to start putting everything into motion and that includes the treat well and the potential help they will bring in helping us across different countries. So we are finalizing the plan as we speak. So we have no specific to deliver to the market for now, but be reassured that we are pretty active in that aspect of the program." That is somewhat general, not granular operational detail like specific numbers, timelines, or how it's being produced. It's more of a status update. Then Lucy asks about IO combination Phase 3 and J&J's commitment. Laurent says they are reviewing what's best, discussing with partner, may do something more powerful. That's not granular operational detail. Then another analyst asks about Hensify in soft tissue sarcoma and LianBio. Laurent says it was part of due diligence, but no specific story. For LianBio, he says they are discussing options, but no specifics. So management is not providing granular operational command. They are giving general updates and future plans.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| WGO | Winnebago Industries, Inc. | Q1 2023 | 2022-12-16 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| AEHR | Aehr Test Systems | Q2 2017 | 2017-01-05 | F |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| ENLC | EnLink Midstream, LLC | Q4 2015 | 2016-02-17 | C+ |
IRT · Q2 2018 → YESThe question is about whether management shows unhesitating, granular operational command on a recently emerged positive element when analysts probe it. YES The transcript shows management providing unhesitating, granular operational detail on the value-add program—a recently emerged positive element whose meaningful contribution began within the last few quarters—as probed by analysts like John Massocca and Craig Kucera. They discuss specifics such as NOI growth from phase 1 rehabs in 4Q 18 (14-15% range), phase 2 as a slight drag, $4.
LTRX · Q3 2024 → YESThe question is about whether management shows unhesitating, granular operational command on a recently emerged positive element when analysts probe it.
NICE · Q4 2023 → YESThe question is about whether management shows unhesitating, granular operational command on a recently emerged positive element when analysts probe it.